K Number
K133635
Device Name
EASYPOINT NEEDLE
Date Cleared
2014-06-17

(203 days)

Product Code
Regulation Number
880.5570
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Easy Point™ Needle is intended for use with syringes for general purpose fluid injection and/or aspiration, and venipuncture to obtain blood collection. The EasyPoint™ Needle aids in the prevention of needlestick injuries.
Device Description
The EasyPoint™ Needle is intended for general purpose percutaneous injection or aspiration of fluids and venipuncture to obtain blood collection. The device contains a sharps injury prevention feature (needlestick prevention feature-chamber) that covers the entire needle after use. Initially available in sizes of 23G and 25G x 1" and 25G x 5/8" for use with 3mL syringes or smaller.
More Information

Not Found

No
The summary describes a mechanical needle with a safety feature and does not mention any AI or ML components or functionalities.

No.
A therapeutic device is one that treats a disease or condition. This device is a needle for injection/aspiration and venipuncture, and its primary function is to aid in preventing needlestick injuries, not to treat a medical condition.

No

The device is a needle intended for general purpose fluid injection and/or aspiration, and venipuncture to obtain blood collection. Its purpose is not to diagnose conditions, but rather to facilitate medical procedures.

No

The device description clearly indicates a physical needle with a sharps injury prevention feature, which is a hardware component. The performance studies also focus on physical characteristics and functionality of the needle.

Based on the provided information, the Easy Point™ Needle is not an In Vitro Diagnostic (IVD) device.

Here's why:

  • Intended Use: The intended use is for "general purpose fluid injection and/or aspiration, and venipuncture to obtain blood collection." This describes a device used directly on a patient for therapeutic or diagnostic sample collection purposes, not for testing samples in vitro (outside the body).
  • Device Description: The description reinforces the intended use for percutaneous injection, aspiration, and blood collection. It focuses on the physical characteristics and safety features related to these procedures.
  • Lack of IVD Characteristics: There is no mention of the device being used to analyze or test biological samples, reagents, or any other components typically associated with IVD devices.

IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The Easy Point™ Needle is a tool for obtaining the specimen, not for performing the diagnostic test itself.

N/A

Intended Use / Indications for Use

The EasyPoint™ Needle is intended for use with syringes for general purpose fluid injection and/or aspiration, and venipuncture to obtain blood collection. The EasyPoint™ Needle aids in the prevention of needlestick injuries. The Easy Point Needle is intended for use with syringes for general purpose fluid injections and venipuncture to obtain blood collection. The Easy Point Needle aids the prevention of needlestick injuries.

Product codes

FMI

Device Description

The EasyPoint™ Needle is intended for general purpose percutaneous injection or aspiration of fluids and venipuncture to obtain blood collection. The device contains a sharps injury prevention feature (needlestick prevention feature-chamber) that covers the entire needle after use. Initially available in sizes of 23G and 25G x 1" and 25G x 5/8" for use with 3mL syringes or smaller.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Engineering Testing: Performance testing on the EasyPoint™ Needle was performed according to applicable design requirements of ISO 594-1, ISO 594-2, ISO 7864, ISO 7886 and ISO 9626. Those tests include, liquid leakage, air leakage, dead space and needle puncture force. Additional performance tests were developed by Retractable Technologies, Inc. to measure the functionality force, deactivation force, chamber strength/ rigidity, cannula/ hub bond strength.

Simulated Use Study: A simulated use pre-market study was performed to demonstrate through human factors validation testing that the EasyPoint™ Needle device performs safely and effectively when used by a variety of healthcare workers in a simulated use scenario.

Comparison of Technical Characteristics: The subject EasyPoint™ Needle utilizes a retraction based safety mechanism like the predicate device VanishPoint® Syringe. The 2nd predicate device, BD PrecisionGlide® single lumen needle is available as a stand-alone needle but does not have an integrated safety mechanism. The BD single lumen needle is also available as a needle/barrel combination syringe. The EasyPoint™ Needle will initially be sold as a stand-alone needle for use with luer fitting devices. The VanishPoint® Syringe and BD single lumen needle are commercially available in various needle length and gauge sizes. Biocompatibility testing has been performed on the EasyPoint™ Needle in accordance with ISO 10993 with acceptable results.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K021475, K970803

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 880.5570 Hypodermic single lumen needle.

(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).

0

K133635

- JUN 1-7-2014`

6/16/14

.


PREMARKET NOTIFICATION 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS FOR VANISHPOINT® BLOOD COLLECTION SET (21 CFR 807.92)

| Applicant Name: | Retractable Technologies, Inc.
511 Lobo Lane
Little Elm, TX 75068 |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phone: | 972-294-1010 |
| Contact Person: | Rhonda Wells
Regulatory Affairs Manager |
| Date of Summary Preparation: | June 16, 2014 |
| Trade Name: | EasyPoint™ Needle |
| Common Name: | Needle, Hypodermic, Single Lumen |
| Regulation Number: | 880.5570 |
| Product Code | FMI: Hypodermic Single Lumen Needle |
| Device Classification: | Class II |
| Legally Marketed Substantially Equivalent Device: | |
| | K021475 - BD Single Lumen Needle (PrecisionGlide™)
K970803 - VanishPoint® Syringe |
| Description of Device: | The EasyPoint™ Needle is intended for general purpose
percutaneous injection or aspiration of fluids and venipuncture to
obtain blood collection.
The device contains a sharps injury prevention feature (needlestick
prevention feature-chamber) that covers the entire needle after use.
Initially available in sizes of 23G and 25G x 1" and 25G x 5/8" for
use with 3mL syringes or smaller. |
| Intended Use: | The Easy Point™ Needle is intended for use with syringes
for general purpose fluid injection and/or aspiration, and
venipuncture to obtain blood collection.
The EasyPoint™ Needle aids in the prevention of needlestick
injuries. |
| Engineering Testing: | Performance testing on the EasyPoint™ Needle was performed
according to applicable design requirements of ISO 594-1, ISO 594-
2, ISO 7864, ISO 7886 and ISO 9626. Those tests include, liquid
leakage, air leakage, dead space and needle puncture force.
Additional performance tests were developed by Retractable
Technologies, Inc. to measure the functionality force, deactivation
force, chamber strength/ rigidity, cannula/ hub bond strength. |
| Simulated Use Study: | A simulated use pre-market study was performed to demonstrate
through human factors validation testing that the EasyPoint™ Needle |

1

device performs safely and effectively when used by a variety of healthcare workers in a simulated use scenario.

Comparison of Technical Characteristics:

The subject EasyPoint™ Needle utilizes a retraction based safety mechanism like the predicate device VanishPoint® Syringe. The 2nd predicate device, BD PrecisionGlide® single lumen needle is available as a stand-alone needle but does not have an integrated safety mechanism. The BD single lumen needle is also available as a needle/barrel combination syringe. The EasyPoint™ Needle will initially be sold as a stand-alone needle for use with luer fitting devices. The VanishPoint® Syringe and BD single lumen needle are commercially available in various needle length and gauge sizes. Biocompatibility testing has been performed on the EasyPoint™ Needle in accordance with ISO 10993 with acceptable results.

Substantial Equivalence:

Conclusion:

The operation, similar design and materials between the subject device and the predicate devices do not raise new issues of safety and effectiveness when used as labeled: The intended use of the subject and predicate devices is virtually identical. In engineering testing, the subject device performed as well or better than the predicate devices. The Simulated Use Study demonstrates that the subject device will perform as intended. The necessary Biocompatibility testing was performed with acceptable results and a Sterilization Validation was performed according to ISO 11137 to ensure sterility of (SAL 106). It is our opinion that the devices are substantially equivalent.

The EasyPoint™ Needle is substantially equivalent to the Vanish Point® Syringe and BD PrecisionGlide® single lumen needle. The intended uses are the same No new concerns regarding safety and effectiveness were raised.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle is enclosed in a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter of the circle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 17, 2014

Retractable Technologies, Incorporated Ms. Rhonda Wells Regulatory Affairs Manager 511 Lobo Lane Little Elm, TX 75068

Re: K133635

Trade/Device Name: EasyPoint™ Needle Regulation Number: 21 CFR 880.5570 Regulation Name: Needle, Hypodermic, Single Lumen Regulatory Class: Il Product Code: FMI Dated: March 18, 2014 Received: March 19, 2014

Dear Ms. Wells:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

3

Page 2 - Ms. Wells

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Mary Runner
-S FILA

Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No, 0910-0120 Expiration Date: January 31, 2017 Sea PRA Statement below.

510(k) Number (if known) KI33632

Device Name

Easy Point Needle

Indications for Use (Describe)

The Easy Point Needle is intended for use with syringes for general purpose fluid injections and venipuncture to obtain blood collection.

The Easy Point Needle aids the prevention of needlestick injuries.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

THE CHIP STORE CONTRACTOR FOR FOR FOR FOR FOR FOR CONTRACTOR CONTRACTOR COLLECT

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Image /page/4/Picture/15 description: The image shows a logo with the letters "FDA" in a stylized, blocky font. The letters are formed by a series of horizontal and vertical lines, creating a grid-like pattern within each letter. The overall design is geometric and somewhat abstract, with a focus on the shapes of the letters rather than a traditional typeface.

Digitally signed by Richard C. Chapman -S Date: 2014.06.16 09:35:17 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*Do NoT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the rine to review instructions, search existing data sources, gather and maintain the data needed and complete line to review instruction. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."